Best Peptides for Muscle Growth in 2026 (and What Bodybuilders Actually Use)

1. How peptides drive muscle growth

Most muscle-growth peptides work upstream, they stimulate the pituitary gland to release more of your own growth hormone (GH), rather than supplying exogenous hormone directly. That upstream stimulus triggers a cascade:

1. GH pulse. The pituitary releases a pulse of GH into circulation. Amplitude and frequency of these pulses decline with age, most adults over 40 are producing 50 to 70% less GH than they did at 20. Peptides restore pulsatility rather than replacing it.
2. IGF-1 synthesis. GH travels to the liver, where it triggers synthesis of Insulin-like Growth Factor 1 (IGF-1). IGF-1 is the primary mediator of GH's anabolic effect on muscle tissue.
3. Satellite cell activation. IGF-1 activates satellite cells, the resident stem cells of skeletal muscle, promoting hypertrophy (cell enlargement) and, at high concentrations, hyperplasia (new fiber formation). This is the direct pathway to lean mass gain.
4. Recovery acceleration. GH and IGF-1 also accelerate collagen synthesis, tendon repair, and sleep-stage recovery, the indirect pathway that lets you train harder and more frequently.

BPC-157 and TB-500 operate through a different mechanism: they work at the tissue level, promoting angiogenesis and cell migration to damaged muscle, tendon, and ligament. They don't raise GH but they enable harder, more frequent training by shortening recovery windows.

2. The 6 peptides with the strongest evidence

This list is ranked by evidence quality (human clinical data weighted over animal data) and practical availability via licensed 503A compounding pharmacy.

3. CJC-1295/Ipamorelin: the foundational GH peptide stack

CJC-1295/Ipamorelin is the most prescribed GH peptide combination in US telehealth. It pairs two complementary mechanisms:

• CJC-1295 (a GHRH analog without DAC) extends the half-life of GHRH-receptor stimulation, amplifying each natural GH pulse.
• Ipamorelin is a selective ghrelin receptor agonist. It triggers additional GH release without the cortisol or prolactin spikes associated with earlier-generation GHRP peptides like GHRP-6.

Together they produce a synergistic pulsatile GH release that is physiologically cleaner than exogenous HGH injections. Clinical studies on GHRH analogs and GHRPs show 1 to 3 kg of lean mass gain over 6 months alongside resistance training, with concurrent reductions in adiposity.

Typical protocol: 0.4 mg/0.4 mg subcutaneous injection 5 evenings per week, timed to align with the natural nocturnal GH surge. Response assessed at 90 days via IGF-1 labs.

Contraindications: Active cancer or cancer history, pituitary tumor history, diabetic retinopathy, pregnancy.

→ Full dosing, syringe math, and response data: CJC-1295/Ipamorelin protocol guide | Compare: CJC-1295/Ipamorelin vs Sermorelin

4. MK-677 (Ibutamoren): oral GH secretagogue

MK-677 is the only oral GH secretagogue available through a licensed 503A compounding pharmacy. It mimics ghrelin at the pituitary and hypothalamus, producing sustained 24-hour elevation of both GH and IGF-1 from a single daily capsule.

A pivotal 2-year randomized controlled trial in elderly adults (Nass et al., NEJM 1998) showed significant increases in IGF-1, lean body mass, and functional performance with MK-677. Subsequent studies confirmed the IGF-1 elevation is dose-dependent and robust across age groups.

Advantages over injectables: No needles, single daily dose, 180-day BUD (capsule stability), convenient for travel.

Disadvantages: Appetite stimulation (the "ghrelin hunger") can be significant, and this is a meaningful obstacle for those trying to maintain a caloric deficit. Water retention (1 to 3 kg in weeks 1 to 4) and mild fasting glucose elevation are the two most common reasons patients discontinue. WADA-prohibited for competitive athletes.

Common misconception: MK-677 is not a SARM. It has no androgenic activity. The confusion arises from its frequent marketing alongside SARMs in the gray-market research chemical space.

Starting dose: 12.5 mg/day for 2 to 4 weeks, then escalate to 25 mg/day if tolerated. Take in the evening to leverage the nocturnal GH pulse.

→ Full protocol: Ibutamoren (MK-677) protocol guide

5. Sermorelin: the gentler GHRH analog

Sermorelin (GRF 1-29) is a truncated form of endogenous GHRH. It is the longest-prescribed GH peptide in the US, used since the 1990s when it briefly held FDA approval for pediatric GH deficiency before being voluntarily withdrawn by the manufacturer (not for safety reasons; the market shifted to recombinant HGH).

Its short half-life (~12 minutes) means the GH pulse is brief and physiologically pulsatile. This is considered an advantage by providers who want a gentler, more "natural" GH stimulus with lower IGF-1 ceilings and a more favorable side-effect profile than longer-acting GHRH analogs or exogenous HGH.

Who it fits: Adults over 30 with age-related GH decline who want sleep quality and body composition improvements without an aggressive protocol. Often the first prescription for peptide-naive patients.

Non-responder rate: ~30 to 40%. IGF-1 labs at 90 days are the decision point. If IGF-1 doesn't move, the provider typically escalates to CJC-1295/Ipamorelin or Tesamorelin.

→ Full protocol: Sermorelin protocol guide | Compare: Tesamorelin vs Sermorelin

6. Tesamorelin: visceral fat + lean mass

Tesamorelin is a stabilized GHRH analog (the native GHRH molecule with a trans-3-hexenoic acid group that extends its half-life) and is the only GH peptide with Phase III clinical trials and an FDA approval (as Egrifta SV for HIV-associated lipodystrophy).

Those Phase III trials showed:

• 15 to 18% reduction in visceral adipose tissue (VAT) over 26 weeks.
• Significant increases in IGF-1 and GH pulse amplitude.
• Improvement in trunk fat-to-lean mass ratio.

For body composition purposes, Tesamorelin occupies a unique position: it is simultaneously the best-evidenced peptide for visceral fat reduction and a robust GH secretagogue for lean mass. Bodybuilders in cutting phases often prefer it over Sermorelin for this reason.

Egrifta vs compounded: Branded Egrifta SV retails at $2,000 to $3,500/month. Compounded Tesamorelin from a 503A pharmacy runs $100 to $200/vial. Same molecule; different economics.

→ Full protocol: Tesamorelin protocol guide

7. BPC-157: recovery from training stress

BPC-157 (Body Protection Compound, a 15-amino acid gastric pentadecapeptide) is not a GH secretagogue and does not directly build muscle. Its role in muscle-growth protocols is recovery, the permissive factor that determines how often and how hard you can train.

Mechanism: BPC-157 upregulates growth factor receptors (VEGFR2, FGFR), promotes angiogenesis at injury sites, and modulates nitric oxide signaling. In rodent models it accelerates repair of muscle tears, tendon ruptures, and ligament damage, all the training-stress injuries that interrupt consistent training.

Evidence caveat: The human RCT data for BPC-157 is thin. Most compelling evidence is preclinical (rodent) or anecdotal from the bodybuilding and sports medicine communities. That said, anecdotal consensus is unusually consistent across sources: faster recovery from tendinopathy, joint pain reduction, and shortened return-to-training timelines.

Why it belongs in muscle-growth stacks: You cannot build muscle tissue during time off. BPC-157's primary value proposition for the physique athlete is injury prevention and rapid return from training injuries.

→ Full protocol: BPC-157 protocol guide

8. TB-500: systemic muscle and tendon repair

TB-500 is a synthetic fragment of Thymosin Beta-4, an actin-sequestering peptide that promotes cell migration, proliferation, and differentiation in damaged tissue. Where BPC-157 drives local repair at the injection site, TB-500 operates more systemically, circulating to sites of damage throughout the body.

In practice the two are almost always combined (as the "Wolverine Stack", BPC-157/TB-500 in a single vial) because their mechanisms are complementary: BPC-157 targets angiogenesis and local growth factor upregulation, while TB-500 drives stem cell migration and reduces systemic inflammation.

Who uses it: Athletes with multiple concurrent soft-tissue injuries, post-surgical patients, and bodybuilders managing chronic overuse injuries from high-volume training.

Evidence status: Similar to BPC-157, strong preclinical, thin human RCT, strong anecdotal. WADA-monitored but not currently on the prohibited list.

9. What bodybuilders actually run (the real-world stacks)

Below are the three most common real-world peptide protocols seen in sports medicine telehealth and discussed in physique athlete communities. These are not endorsements, they are a descriptive account of what prescribers report seeing.

Bodybuilder stacks: pre-contest, off-season, recovery phase

Off-season (lean mass focus)

• CJC-1295/Ipamorelin: 0.4 mg/0.4 mg 5 nights/week
• MK-677: 12.5 to 25 mg orally each evening
• BPC-157: 0.5 to 1 mg/day for ongoing joint/tendon support

Rationale: The CJC/Ipa stack drives GH pulse amplitude; MK-677 sustains IGF-1 elevation around the clock; BPC-157 handles the tendon stress that high-volume off-season training generates.

Pre-contest (recomposition focus)

• Tesamorelin: 0.6 to 1.6 mg/day (with Ipamorelin for dual-pathway activation)
• BPC-157/TB-500 (Wolverine Stack), 0.6 mg/0.6 mg 5 days/week

Rationale: Tesamorelin's superior visceral fat evidence makes it the preferred cutting-phase GH secretagogue. The Wolverine Stack maintains recovery capacity during the high-stress pre-contest phase when caloric restriction and high training volume converge.

Recovery phase (post-injury or post-surgery)

• BPC-157/TB-500 (Wolverine Stack), 5 days/week for 8 to 12 weeks
• Sermorelin: nightly, to maintain GH pulsatility during reduced-training period

Rationale: Maximize tissue healing rate while keeping GH axis active at a gentler stimulus level appropriate for a period of reduced training intensity.

10. What peptides will NOT do (the SARM/AAS comparison)

This section exists because the marketing around peptides has become increasingly hyperbolic. The honest comparison:

The bottom line: GH peptides are not "legal steroids." They are hormonal optimization tools with a favorable safety profile relative to androgens, meaningful body composition benefits, and a legitimate prescription pathway. Their effect size on muscle mass is real but modest.

11. Honest evidence ranking

1. Tesamorelin: Tier 1. Phase III RCTs, FDA approval. The gold standard of evidence in the GH peptide category.
2. MK-677 (Ibutamoren): Tier 1. Multiple randomized controlled trials including a 2-year NEJM study. Reproducible IGF-1 elevation with known side-effect profile.
3. Sermorelin: Tier 2. Decades of clinical use, FDA-approved history (withdrawn voluntarily, not for safety). Strong safety track record; leaner RCT data on lean mass than the Tier 1 agents.
4. CJC-1295/Ipamorelin: Tier 2. Individual components have clinical data; the combination is widely prescribed with good real-world safety data but fewer head-to-head RCTs than Tesamorelin or MK-677.
5. BPC-157: Tier 3. Strong rodent data, no completed human RCTs. High anecdotal consensus. Use with informed expectations.
6. TB-500: Tier 3. Same evidence tier as BPC-157. Typically stacked with BPC-157 rather than used independently.

12. How to get a prescription for muscle-growth peptides

All six peptides listed above are available through a licensed telehealth provider and 503A compounding pharmacy. The process:

1. Online intake. Complete a structured health history including current medications, cancer history, and goals. No in-person clinic visit required.
2. Provider review. A licensed provider reviews your intake and, where relevant, existing labs. IGF-1 and basic metabolic panel are useful baseline labs but are not always required for initial prescription.
3. Prescription and fill. The provider sends a prescription to a licensed 503A pharmacy (Optimal Balance Pharmacy for RxPepsDirect patients). Compounded peptides are pre-reconstituted and shipped FedEx overnight, no bacteriostatic water required.
4. Monitoring. IGF-1 labs at 90 days determine whether to continue, dose-adjust, or switch peptides. Providers on the RxPepsDirect platform offer ongoing asynchronous check-ins.

Eligible states (as of June 2026): Alaska, Arizona, Colorado, Connecticut, Delaware, District of Columbia, Florida, Idaho, Indiana, Iowa, Kansas, Louisiana, Maine, Michigan, Montana, Nevada, New Hampshire, New Jersey, New York, North Dakota, Pennsylvania, Rhode Island, Texas, Utah, Vermont, Washington, Wisconsin, Wyoming.